2 matches for your search in the start-up spotlight
rss
matching the following criteria
Sort by:
Hedera Dx
Founded in Switzerland in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, Hedera Dx is on a mission to make liquid biopsies a reality in clinical practice globally, in order to help more cancer patients get better therapy options and better outcomes. The Hedera Dx liquid biopsy ...
Elypta AB
Elypta is developing the first-ever metabolism-based liquid biopsy platform for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, exceptionally sensitive in studies to date and the low cost assay technology allows for broad use. ...
